These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 7424645)

  • 1. Studies with allopurinol in patients with impaired renal function.
    Elion GB; Benezra FM; Beardmore TD; Kelley WN
    Adv Exp Med Biol; 1980; 122A():263-7. PubMed ID: 7424645
    [No Abstract]   [Full Text] [Related]  

  • 2. Absorption and metabolism of allopurinol and oxypurinol by rat jejunum in vitro: effects on uric acid transport.
    Shaw MI; Parsons DS
    Clin Sci (Lond); 1984 Mar; 66(3):257-67. PubMed ID: 6692658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Letter by Kielstein et al regarding article, "High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid".
    Kielstein JT; Woywodt A; Salpeter SR
    Circulation; 2007 May; 115(18):e450-1; author reply e451. PubMed ID: 17485587
    [No Abstract]   [Full Text] [Related]  

  • 4. Renal clearances of purine bases and oxypurinol during glucose infusion.
    Moriwaki Y; Yamamoto T; Takahashi S; Nasako Y; Hada T; Higashino K
    Adv Exp Med Biol; 1994; 370():39-42. PubMed ID: 7660935
    [No Abstract]   [Full Text] [Related]  

  • 5. Orotidine accumulation in human erythrocytes during allopurinol therapy: association with high urinary oxypurinol-7-riboside concentrations in renal failure and in the Lesch-Nyhan syndrome.
    Simmonds HA; Reiter S; Davies PM; Cameron JS
    Clin Sci (Lond); 1991 Mar; 80(3):191-7. PubMed ID: 1850677
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship between serum urate and plasma oxypurinol in the management of gout: determination of minimum plasma oxypurinol concentration to achieve a target serum urate level.
    Stamp LK; Barclay ML; O'Donnell JL; Zhang M; Drake J; Frampton C; Chapman PT
    Clin Pharmacol Ther; 2011 Sep; 90(3):392-8. PubMed ID: 21796116
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Renal insufficiency and uric acid metabolism: harmful effect of uric acid and new interpretation of uric acid metabolism].
    Suzuki Y; Mimura N
    Nihon Rinsho; 1974 Mar; 32(3):488-95. PubMed ID: 4603800
    [No Abstract]   [Full Text] [Related]  

  • 8. Investigation of the transport of xanthine dehydrogenase inhibitors by the urate transporter ABCG2.
    Nakamura M; Fujita K; Toyoda Y; Takada T; Hasegawa H; Ichida K
    Drug Metab Pharmacokinet; 2018 Feb; 33(1):77-81. PubMed ID: 29342419
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Metabolic disorder of purine nucleotide in patients with chronic renal failure].
    Hosoya T; Tabe A; Hayashi T; Sakai O
    Nihon Rinsho; 1992 Jan; 50 Suppl():544-8. PubMed ID: 1578736
    [No Abstract]   [Full Text] [Related]  

  • 10. Xanthine-containing calculi during allopurinol therapy.
    Kranen S; Keough D; Gordon RB; Emmerson BT
    J Urol; 1985 Apr; 133(4):658-9. PubMed ID: 3981718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Purine metabolism in patients with renal failure].
    Hosoya T; Ohno I; Uetake D; Saikawa H
    Nihon Rinsho; 2004 Jun; 62 Suppl 6():136-41. PubMed ID: 15250282
    [No Abstract]   [Full Text] [Related]  

  • 12. Effect of glucose infusion on the renal transport of purine bases and oxypurinol.
    Moriwaki Y; Yamamoto T; Takahashi S; Suda M; Higashino K
    Nephron; 1995; 69(4):424-7. PubMed ID: 7777107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level.
    Siu YP; Leung KT; Tong MK; Kwan TH
    Am J Kidney Dis; 2006 Jan; 47(1):51-9. PubMed ID: 16377385
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allopurinol and oxypurinol are hydroxyl radical scavengers.
    Moorhouse PC; Grootveld M; Halliwell B; Quinlan JG; Gutteridge JM
    FEBS Lett; 1987 Mar; 213(1):23-8. PubMed ID: 3030809
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma oxypurinol concentration in a patient with allopurinol hypersensitivity.
    Puig JG; Casas EA; Ramos TH; Michán AA; Mateos FA
    J Rheumatol; 1989 Jun; 16(6):842-4. PubMed ID: 2528636
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cerebrospinal fluid versus serum concentrations of 5-FU, allopurinol, and oxypurinol during treatment of metastatic brain cancer with 5-FU infusion, allopurinol, and radiation.
    Hornbeck CL; Floyd RA; Byfield JE; Griffiths JC; Frankel S; Sharp TR
    Cancer Treat Rep; 1982 Mar; 66(3):571-3. PubMed ID: 7060045
    [No Abstract]   [Full Text] [Related]  

  • 17. Higher therapeutic plasma oxypurinol concentrations might be required for gouty patients with chronic kidney disease.
    Panomvana D; Sripradit S; Angthararak S
    J Clin Rheumatol; 2008 Feb; 14(1):6-11. PubMed ID: 18431090
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of dietary protein on the clearance of allopurinol and oxypurinol.
    Berlinger WG; Park GD; Spector R
    N Engl J Med; 1985 Sep; 313(13):771-6. PubMed ID: 4033706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sustained reductions in oxipurinol renal clearance during a restricted diet.
    Park GD; Berlinger WG; Spector R; Kitt TM; Tsalikian E
    Clin Pharmacol Ther; 1987 Jun; 41(6):616-21. PubMed ID: 3581647
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-responsiveness to allopurinol in renal hypouricaemia.
    Löffler W; Seibke W; Seibke E; Reiter S; Jahn M; Hehlmann R; Zöllner N
    Klin Wochenschr; 1989 Jan; 67(1):47. PubMed ID: 2921842
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.